Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma
Barber, Thomas, Kenkre, Julia, Garnett, Catherine, Scott, Rebecca V., Byrne, James V. and Wass, John A. H.. (2011) Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma. Clinical Endocrinology, 75 (6). pp. 819-824. ISSN 0300-0664Full text not available from this repository.
Official URL: http://dx.doi.org/10.1111/j.1365-2265.2011.04136.x
Context The optimal duration of dopamine agonist (DA) therapy in prolactinoma is unknown. There are concerns that despite low recurrence rates in highly selected groups, high recurrence rates after DA withdrawal may occur in routine practice.
Objective To explore recurrence of hyperprolactinaemia and predictive factors following DA withdrawal in patients with microprolactinoma and macroprolactinoma.
Design A retrospective study on adult patients with confirmed prolactinoma attending the Oxford Endocrine Department.
Patients and Measurements We identified patients with macroprolactinoma (n = 15) and microprolactinoma (n = 45) treated with DA therapy for >3 years, with a trial off DA therapy. None had other treatments. Measurements included recurrence of hyperprolactinaemia following DA withdrawal, tumour size (macroprolactinomas), duration of DA therapy, prolactin levels (baseline, during DA therapy, recurrence) and time to recurrence. Data were reported as mean (range).
Results During DA therapy, prolactin levels suppressed to normal range in all patients with macroprolactinoma and microprolactinoma, and most macroprolactinomas (n = 14) had substantial tumour shrinkage. Hyperprolactinaemia recurred in 93% of macroprolactinomas (n = 14) at 8·8 months (3–36) and 64% of microprolactinomas (n = 29) at 4·8 months (3–12). Duration of DA therapy was 7·5 years (4–15) for macroprolactinomas and 4·1 years (3–10) for microprolactinomas. Prolactin levels during DA therapy were 144 mU/l (7–336) for macroprolactinomas and 278 mU/l (30–629) for microprolactinomas. For microprolactinomas, prolactin levels during DA therapy were less suppressed in those with recurrence than in those without recurrence (P < 0·05).
Conclusions In routine practice, hyperprolactinaemia recurs early in most macroprolactinomas (93%) and microprolactinomas (64%) following DA therapy discontinuation. For most macroprolactinomas, cessation of DA cannot be recommended even after 7 years of therapy.
|Item Type:||Journal Article|
|Subjects:||R Medicine > R Medicine (General)|
|Divisions:||Faculty of Medicine > Warwick Medical School > Biomedical Sciences > Translational & Experimental Medicine > Metabolic and Vascular Health (- until July 2016)
Faculty of Medicine > Warwick Medical School
|Journal or Publication Title:||Clinical Endocrinology|
|Publisher:||Wiley-Blackwell Publishing Ltd|
|Official Date:||December 2011|
|Page Range:||pp. 819-824|
|Access rights to Published version:||Restricted or Subscription Access|
Actions (login required)